“…While we appreciate the short –term use of buprenorphine/naloxone, clinicians should continue to monitor a patients response since there have been a number of issues involving toxicity(DeVido, Connery, & Hill, 2015; Gangahar, 2015; Daniulaityte, Carlson, Brigham, Cameron, & Sheth, 2015; Ciftci et al, 2015; Edwards, McCormick-Deaton, & Hosanagar, 2014; Lavonas et al, 2013; Kim, Smiddy, Hoffman, & Nelson, 2012). One limited study suggests that buprenorphine does not affect the cingulate gyrus in early abstinent heroin addicts and as such may act as a true non-addicting pharmaceutical to prevent relapse (Mei, Zhang, & Xiao, 2010); clearly much more research is needed on this topic.…”